TheraRadar
Data updated: May 26, 2026

FULVICIN P/G (griseofulvin, ultramicrosize)

Infectious Disease Approved 1982-04-06

FULVICIN P/G is indicated for the treatment of Tinea Corporis; Tinea Pedis; Tinea Cruris; Tinea Barbae; Tinea Capitis; Onychomycosis.

Source: FDA Label • CHARTWELL RX
1
Indication
--
Phase 3 Trials
44
Years on Market

Details

Status
Prescription
First Approved
1982-04-06
Routes
ORAL
Dosage Forms
TABLET

Companies

Active Ingredient: GRISEOFULVIN, ULTRAMICROSIZE

FULVICIN P/G Approval History

1983
1984
1985
1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
4 FDA actions from 1982 to 2001
Jan 2001 SUPPL
Mfg · Manufacturing (CMC)
Apr 1982 ORIGINAL
Update

What FULVICIN P/G Treats

6 indications

FULVICIN P/G is approved for 6 conditions since its original approval in 1982. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Tinea Corporis
  • Tinea Pedis
  • Tinea Cruris
  • Tinea Barbae
  • Tinea Capitis
  • Onychomycosis
Source: FDA Label

FULVICIN P/G Competitive Set

Pro

Three rings of competition based on shared molecular targets and treated indications.

Unlock 6 more competitors across all three rings.
Upgrade to Pro

Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.

Drugs Similar to FULVICIN P/G

3 of 20

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

FULVICIN P/G 165
GRISEOFULVIN, ULTRAMICROSIZE
6 shared
CHARTWELL RX
Shared indications:
FULVICIN-U/F
GRISEOFULVIN, MICROSIZE
6 shared
CHARTWELL RX
Shared indications:
Tinea CapitisTinea CorporisTinea Pedis +3 more
GRISEOFULVIN
GRISEOFULVIN, MICROSIZE
5 shared
CHARTWELL RX
Shared indications:
Tinea capitisTinea corporisTinea cruris +2 more
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

FULVICIN P/G FDA Label Details

Indications & Usage

FULVICIN P/G is indicated for the treatment of Tinea Corporis; Tinea Pedis; Tinea Cruris; Tinea Barbae; Tinea Capitis; Onychomycosis.

Track FULVICIN P/G with TheraRadar Pro

Watchlist alerts, full database access, CSV exports across 14,000+ drugs.

Upgrade to Pro

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.